Additional strong support for COX-2-independent anti-tumor effects of celecoxib has come from the use of its close structural analog, 2,5-dimethyl-celecoxib (DMC) (.)[33], which lacks COX-2 inhibitory function, yet was shown to faithfully mimic the anti-tumor effects of celecoxib in various experimental systems, including the reduction of neovascularization and the inhibition of experimental tumor growth in prostate carcinoma and Burkitt's lymphoma xenograft mouse tumor models [21,25,26,28-32]. Here, PTGS2 is linked to neoplasm.